BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Leiner T, Kucharczyk W. Special issue: nephrogenic systemic fibrosis. J Magn Reson Imaging 2009;30:1233-5. [PMID: 19938034 DOI: 10.1002/jmri.21985] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Sato T, Tamada T, Watanabe S, Nishimura H, Kanki A, Noda Y, Higaki A, Yamamoto A, Ito K. Tissue gadolinium deposition in hepatorenally impaired rats exposed to Gd-EOB-DTPA: evaluation with inductively coupled plasma mass spectrometry (ICP-MS). Radiol med 2015;120:557-62. [DOI: 10.1007/s11547-014-0492-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
2 Verwilst P, Park S, Yoon B, Kim JS. Recent advances in Gd-chelate based bimodal optical/MRI contrast agents. Chem Soc Rev 2015;44:1791-806. [DOI: 10.1039/c4cs00336e] [Cited by in Crossref: 100] [Cited by in F6Publishing: 23] [Article Influence: 14.3] [Reference Citation Analysis]
3 Viswanathan S, Kovacs Z, Green KN, Ratnakar SJ, Sherry AD. Alternatives to gadolinium-based metal chelates for magnetic resonance imaging. Chem Rev 2010;110:2960-3018. [PMID: 20397688 DOI: 10.1021/cr900284a] [Cited by in Crossref: 332] [Cited by in F6Publishing: 280] [Article Influence: 27.7] [Reference Citation Analysis]
4 Morse DL, Gillies RJ. Molecular imaging and targeted therapies. Biochem Pharmacol 2010;80:731-8. [PMID: 20399197 DOI: 10.1016/j.bcp.2010.04.011] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
5 Edwards BJ, Laumann AE, Nardone B, Miller FH, Restaino J, Raisch DW, McKoy JM, Hammel JA, Bhatt K, Bauer K, Samaras AT, Fisher MJ, Bull C, Saddleton E, Belknap SM, Thomsen HS, Kanal E, Cowper SE, Abu Alfa AK, West DP. Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a Research on Adverse Drug Events and Reports (RADAR) report. Br J Radiol 2014;87:20140307. [PMID: 25230161 DOI: 10.1259/bjr.20140307] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
6 Fretellier N, Idée JM, Guerret S, Hollenbeck C, Hartmann D, González W, Robic C, Port M, Corot C. Clinical, biological, and skin histopathologic effects of ionic macrocyclic and nonionic linear gadolinium chelates in a rat model of nephrogenic systemic fibrosis. Invest Radiol 2011;46:85-93. [PMID: 20938344 DOI: 10.1097/RLI.0b013e3181f54044] [Cited by in Crossref: 44] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
7 Sato T, Ito K, Tamada T, Kanki A, Watanabe S, Nishimura H, Tanimoto D, Higashi H, Yamamoto A. Tissue gadolinium deposition in renally impaired rats exposed to different gadolinium-based MRI contrast agents: Evaluation with inductively coupled plasma mass spectrometry (ICP-MS). Magnetic Resonance Imaging 2013;31:1412-7. [DOI: 10.1016/j.mri.2013.03.025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
8 Yang C, Padmanabhan P, Gulyás BZ. Gadolinium( iii ) based nanoparticles for T 1 -weighted magnetic resonance imaging probes. RSC Adv 2016;6:60945-66. [DOI: 10.1039/c6ra07782j] [Cited by in Crossref: 27] [Article Influence: 4.5] [Reference Citation Analysis]